Good morning, and welcome to the Soterra Health First Quarter 2026 Earnings Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on a touch-tone phone. To withdraw your question, please press star then two. Please note, this event is being recorded. I would now like to turn the conference over to Vice President of Investor Relations, Jason Peterson. Jason, please go ahead.

Good morning and thank you. Welcome to Sotera Health's first quarter earnings call. Today's press release and supplemental slides are available on the investor section of our website at SoteraHealth.com. This webcast is being recorded and a replay also will be available on the investor section of the Sotera Health website shortly after the call. Joining me today are Chairman and Chief Executive Officer Michael Petras and Chief Financial Officer John Lyons. During today's call, some of our comments may be considered forward-looking statements. The matters addressed in these statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Please refer to Sarah Health's SEC filings in the forward-looking statement slide at the beginning of the presentation for a description of these risks and uncertainties. The company assumes no obligation to update any such forward-looking statements. Please note that during the discussion today, the company will present both GAAP and non-GAAP financial measures, including adjusted EBITDA, adjusted EBITDA margin, tax rate applicable to net income, adjusted net income, adjusted EPS, adjusted free cash flow, net debt, and net leverage ratio, as well as constant currency comparisons. A reconciliation of GAAP to non-GAAP measures for all relevant periods may be found in the schedules attached to the company's press release and in the supplemental slides to this presentation. The operator will be assisting with the Q&A portion of the call today. Please limit yourself to one question and one follow-up. For further questions, feel free to reach out to the investor relations team. With that, I'll now turn the call over to Cetera Health Chairman and CEO, Michael Petros.

Good morning, everyone, and thank you for joining us today. This morning, we announced a strong start to the year with 6.5% constant currency revenue growth and 6.9% constant currency adjusted EBITDA growth, driving over 20 basis points of margin expansion compared to the first quarter of last year. Sterigenics delivered 6.1% constant currency revenue growth in a quarter, while Norion grew constant currency revenue 25.8% and expanded margins by over 290 basis points. Nelson Labs' results were in line with the expectations we outlined on our last earnings call. Today, we are reaffirming our 2026 outlook provided during our February earnings call. As a reminder, we expect total company revenue to increase through a range of $1.23 billion to $1.25 billion, representing constant currency growth of 5% to 6.5% versus 2025. and adjusted EBITDA to grow to a range of $632 million to $641 million, or 5.5% to 7% constant currency growth. As we reaffirm our full-year outlook, I want to reiterate the strength and resiliency of our business model. We provide mission-critical regulated services that are deeply embedded in our customer supply chains. More than 70% of our revenue is supported by multi-year contracts, serving long-tenured customer relationships through a global network of facilities. Our commitment to customers is a core company value, and in 2025, we delivered substantial improvements in our customer satisfaction scores across both Sterigenics and Nelson Labs. Our business model has demonstrated its resilience over time, delivering consistent revenue growth for the past two decades across multiple economic cycles. We sit in a unique position in the healthcare supply chain and take our mission of safeguarding global health very seriously. John will get into the financial details in a moment, but first I want to take the time to highlight some events that took place during the quarter. On the governance front, in addition to adding Rich Kyle to our board of directors in February, we're excited to welcome Ken Krause, who joined our board in March. Ken's leadership and proven track record of creating shareholder value as a public company chief financial officer for over 10 years, combined with his extensive experience in strategy, finance, and governance, will be tremendous assets as we continue to grow. I'd also like to thank Dean Mijas and Robert Knauss, two of our private equity board members, for their service and contributions to Cetera Health. Dean recently completed his board service, and Rob will transition off the board later this month. Both have provided valuable perspective and guidance, and we sincerely appreciate their impact over the years. In March, the private equity shareholders completed another secondary sale of existing shares, bringing our public float to approximately 90% of outstanding shares. Lastly, I want to briefly comment on some positive legal developments in Georgia. As a reminder, eight bellwether personal injury cases were selected into Phase I and Phase II causation proceedings where the court focused on the science. On March 30, 2026, the Georgia State Court dismissed the remaining five bellwether cases as the plaintiffs could not prove general causation in the Phase I proceedings. As a reminder, the court dismissed the other three bellwether cases in October of last year in the Phase II specific causation proceedings. All eight bellwether cases have now been dismissed and are subject to appeal. Although the March 30th order applies directly to the five Phase I pool cases, the court's rejection of plaintiff's general causation theories is a critical issue common to all of the personal injury cases. We believe this order underscores the lack of reliable scientific support for those remaining claims and should inform how the remaining cases are evaluated. We will continue to put sound science at the center of our defense as we stand behind the safety and importance of Sterigenics operations. As a reminder, developments related to EO can be found on our investor's website. Now, John will take us through the financials in more detail.

Thank you, Michael. I will begin by covering the first quarter 2026 highlights on a consolidated basis and then provide some details on each of business segments. I will then wrap up with additional details on our 2026 outlook. For the first quarter on a consolidated total company basis, revenues increased by 10% to $280 million or 6.5% on a constant currency basis compared to the first quarter 2025. Net income on a gap basis for the quarter was $27 million or nine cents per diluted share. Adjusted EVA dog grew 10.5% to $135 million, or 6.9% on a constant currency basis, while adjusted EBITDA margins expanded to over 20 basis points. Interest expense for Q1-2026 improved by $6 million to $35 million compared to the prior year quarter. Approximately half of the improvement was driven by the term loan repricing and debt paydown completed late in the third quarter of 2025, with the remainder driven by lower interest rates. adjusted EPS increased to 18 cents per share an improvement of approximately 29 percent from the prior year it was a strong first quarter overall with results largely in line with our expectations aside from some favorable timing in Nordeon now let's go through the segment results Sterigenics delivered 9.7 percent revenue growth to 186 million dollars or 6.1 percent on a constant currency basis. Favorable pricing of 4.5%, a foreign currency benefit of 3.6%, and improved volume and mix of 1.6% drove revenue growth for the quarter. Localized weather impacts in the U.S. during Q1 resulted in a 1.7% headwind to Sterigenics volumes versus the prior year quarter. Segment income grew 9.6% to $96 million, or 6% on a constant currency basis, driven by favorable pricing, a foreign currency tailwind, and improved volume mix, partially offset by higher costs. Nordeon's first quarter revenue increased 29% to $42 million, or 25.8% on a constant currency basis, compared to the same period last year, driven primarily by increased volume mix of 23.7% due to the timing of cobalt-60 harvest schedules, along with foreign currency tailwinds of 3.2 percent and a pricing benefit of 2.1 percent. Nordian's segment income increased approximately 36 percent to $24 million or 33.1 percent on a constant currency basis with segment income margins expanding more than 290 basis points to 56.4 percent driven by higher volume mix, foreign currency benefits, and favorable pricing partially offset by inflation. Nelson Labs' revenue declined 0.7% to $52 million, or 3.8% on a constant currency basis. Pricing benefits of 2.8% and a foreign currency benefit of 3.1% were more than offset by the change in volume and mix. Segment income decreased by 11.5% to $15 million, or 15.1% on a constant currency basis, with margins of 28%, reflecting lower volume in the mix, partially offset by favorable pricing and a foreign currency tailwind. Now, I will touch on the balance sheet, cash generation, and capital deployment. In the first quarter, we generated $29 million in positive operating cash flow, inclusive of a $34 million payment for a previously disclosed legal settlement. We had positive adjusted free cash flow, which will accelerate throughout the year. Total expenditures for the quarter totaled $46 million as we continued to make progress on our SterigenX greenfield expansions, EO facility upgrades, and Cobalt-60 development projects. The company's liquidity position remained strong. As of the end of Q1-2026, we had over $900 million of available liquidity. We finished the quarter with a net leverage ratio of 3.2 times, nearing our long-term target range of two to three times. As Michael mentioned, we are reaffirming our 2026 outlook. To recap, we expect the following as compared to 2025. Total company revenue to grow to a range of $1.233 billion to $1.251 billion, representing 5% to 6.5% constant currency growth, and an estimated 100 basis point foreign currency benefit. We expect adjusted EBITDA to improve to a range of $632 million to $641 million, representing 5.5% to 7% constant currency growth and an estimated 100 basis point impact from foreign currency. The foreign exchange benefit is expected to be fully realized in the first half of 2026, with the second half impact expected to be approximately neutral versus the prior year. Company pricing is expected to be approximately the midpoint of our 3% to 4% long-term range. For 2026, we expect Sterigenics to deliver mid- to high-single-digits constant currency revenue growth year-over-year, with the second quarter year-over-year growth similar to the first quarter of 2026. As a reminder, Q2 was our strongest quarter of growth in 2025. We expect Nordeon to grow constant currency revenue in the low- to mid-single digits in 2026. Nordeon's first half revenue is expected to represent approximately 40% to 45% of full-year 2026 revenue. For Nelson Labs, we expect full-year 2026 constant currency revenue growth to be in the low single digits, with a slight return to growth in Q2. Segment income margins at Nelson Labs are expected to improve throughout the year, resulting in full-year margins in the low to mid-30s. In the current forward rate curve, we expect interest expense between $135 million and $145 million. We are projecting an effective tax rate applicable to adjusted net income in the range of 27 to 29 percent. We expect adjusted EPS in the range of 93 cents to $1.01. We continue to expect depreciation to increase in 2026, consistent with the step-up we experienced in 2025. On a weighted average basis, we expect a fully diluted share count in the range of $289 million to $291 million shares. Full expenditures are expected to be in the range of $175 million to $225 million. We anticipate further net leverage ratio improvement in 2026. Finally, as usual, our guidance does not assume any M&A activity. Now I'll turn the call back over to Michael.

It has been my privilege to serve Sotero Health as CEO and chair since 2016. With the company on strong footing after a decade of progress, I believe the time is right for a leadership transition that supports Sotero Health's continued evolution. Following a thoroughly planned, board-led succession process, the board has appointed Alton Shader as Sotero Health's new chief executive officer, effective May 26th. Alton is a seasoned healthcare executive with significant experience leading and growing global healthcare organizations, including Viant Medical, Hill-Rom, and Baxter. In my new role as Executive Chair and as a meaningful investor in this company, I look forward to working closely with Alton to ensure a smooth and deliberate leadership transition. We have already started discussing priorities and the path forward for Sotera Health. I also continue to be actively involved in investor relations and commercial and litigation strategies. In addition to my new role, I want to thank our board for its guidance and support over the past decade. I want to thank our 3,100 employees for working with me and our leaders and continuing to make this company really special and a great place to work. I also want to thank our investors for your support since we took the company public in 2020. Rest assured, I continue to believe in and will remain engaged and committed to the long-term success of our company. With that, Operator, I'd like to open it up for questions.

Thank you. we will now begin the question and answer session. To ask a question, you may press star then one on a touchtone phone. If you're using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star then two. At this time, we will pause momentarily to assemble our roster. The first question today comes from Sean Dodge with BMO Capital Markets. Please go ahead.

Hey, good morning. This is Thomas Keller on for Sean. I guess first off, congratulations on 10 years, Michael. Thank you for taking the questions. I wanted to start off on Sterigenics and the realignment of the business around higher growth and markets. Where are you all in that strategy? I imagine it takes some time to get the pieces in place internally for that and then to win and onboard new business. Was there any benefit here from a volume or mix shift standpoint in Q1 or is there anything contemplated in the full year guide? Thanks.

Yeah, thanks, Thomas. You know, That's something that we're focused on as an organization. As we look at our cross-business unit activity and our strategic selling activity, we're focused on those key segments. In the quarter, Sterigenics put up 1.6% volume of mixed growth. And then remember, we also had an impact from weather. So we're happy. The first quarter, the beginning of the quarter started off slow with the weather, which we kind of signaled when we talked last time. But it finished strong, and we're optimistic on the outlook as we go forward here in how March finished out and how we're starting out the second quarter.

Okay, that's great. And then from a capacity standpoint, where's the business now in terms of utilization kind of across the different modalities, maybe versus historical averages? And with remaining expansions, do you have what you need to support potentially higher level of growth for the next several years?

Yeah, thank you. Yeah, we're in a good spot on capacity. Obviously, by modality, by geography, you'll have some pinch points at a given point in time. But, you know, we target 80%. We're in a good spot. The teams have done a nice job operationally to try to figure out how to get more out of our existing capacity. You know, we've got a facility that we'll start to bring online later this year in the X-ray modality. And then we've got another one scheduled late 27, early 28 that we feel good about. So, overall, our capacity situation's in a good spot. We're well-situated and been servicing our customers very well. I also referenced on the call, you know, we continue to see good customer satisfaction scores. We just got the results for 2025, and we saw significant improvement year over year, so both in Sterigenics and Nelson Labs. So we're going the right direction. We're really encouraged what we see going forward here.

All right, great. Thank you very much, and congrats again.

Thank you.

The next question comes from Brett Fishman with KeyBank Capital Markets. Please go ahead.

Hey, good morning, everyone. Just a quick question on Sterigenics. 1Q is generally expected to be the lightest quarter for that segment, and you somewhat exceeded expectations. Do you still see 1Q as being the lightest quarter of the year? And then maybe just to tag on to follow on, can you just speak a little bit to what you're seeing within core med devices and bioprocessing volumes specific to sterogenics?

You know, we saw a nice quarter out of sterogenics. We'd like to see it a little bit better, but obviously we can't control the weather. You know, last year we had a significant second quarter, as we've talked about in the past. We'll see a good quarter here in the second quarter, consistent with the guide that we've just provided you. You know, we're expecting similar growth to the first quarter in constant currency. And MedDevice had a good solid quarter. When you look across, all the end markets we serve, MedDevice had a good solid quarter, and bioprocessing was up significant year over year again. But remember, it's a small portion of our total business, but it was significant growth over prior.

Yeah, thank you very much. It's helpful.

The next question comes from Patrick Dinelli with Citi. Please go ahead.

Hey, guys. Thanks for the question. Michael, congrats. I'm turning the Irishman into an Italian.

Dinelli? All right, go ahead, Patrick.

Yeah, it's a first. congrats on the move, the transition. And I guess maybe one on Sterigenics. Can you just talk about what you saw as the quarter progressed on the volume side, just the visibility there? It feels like you're in a pretty good spot, but just maybe talk through the different markets and what you saw as the quarter progressed and the expectations here going forward.

Yeah, Patrick, you know, January and February were a little softer, as I mentioned, particularly, you know, weather-related. But as the quarter progressed, March, you know, You know, March was the best quarter on volume we've had in the last three or four years in March. So, you know, one month doesn't make a year, but we're optimistic about that. And April started out strong. So we feel very comfortable in the guide that we've given here, and we're seeing nice growth. And we expect that to continue as the year progresses with some of the things. You know, we've got that x-ray facility coming out. We'll see some growth of that. we've got a customer conversion that we've talked about previously they'll start to impact late in the year and then overall just the level of engagement with our customers and some of the commitments that we see coming forth from them we feel good about how stereogenics is positioned coming out of the first quarter that's helpful and then maybe just on the margin side can you talk through the moving pieces you know obviously pricing always a good lever for you guys any changes on that front and just how we should think about the margins as we work our way through the year.

Thank you, guys.

Yeah, Patrick, it's John. Thanks for the question. You know, we feel good about the margins, as the guide implies, right? We've got a, we saw margin, well, we saw margin improvement in the quarter. As the guide implies, we expect margin improvement in the year. That's really going to be driven from Sterigenics, where we expect to get some good operating leverage in the business and really stable margins on the other part of the segments.

But we're very optimistic about the opportunity to see another year of margin improvement on the heels of our strong margin improvement last year so we're feeling good about that the next question comes from max smock with william blair please go ahead hi good morning guys and thanks for taking our questions i'm going to try to hit on the sterigenics question another way here i think you know excluding the weather in fact you did about eight percent constant currency uh in one queue said you expect you know similar constant currency growth in two queue even though you know april's off to a strong start you don't have that weather piece. Is that slowdown relative to the 8% X weather? Is that just a comp issue? Is it just conservatism? Or are there some other factors in there we should be thinking about for sterogenics in the second quarter? Thank you.

Yeah, thanks, Max. The big thing, and I alluded to it in my script, Q2 of last year was our strongest quarter of growth. So it's really a comp issue versus anything else.

Okay. Yeah, that's helpful. Just wanted to confirm on that. And then maybe one on nelson labs here um and i know you said it was in line with your expectations for the quarter just wondering if you could help us think through you know testing growth versus expert advisory services and in particular how much of a headwind the latter represented in 2q and then just thinking through you know the margins did step down pretty significantly year over year so helping us understand the drivers behind that and then the outlook for margins for that segment uh over the balance of the year as well would be super helpful thank you yep uh great max um this is michael as we communicated, it came in as we expected, what we were seeing on the Nelson side for the first quarter.

EAS, this is the last quarter where we had that headwind that we're lapping over. Testing volumes were down a little bit over a prior year, but as we look at some of the activity, routine volumes are coming back. Our service has been outstanding in that area, and as sterilizations volume go up, we'll continue to see that correlation and strength on the routine testing side. Not always one-for-one, but there is a correlation there. And then on the validation side, we're starting to see some pipelines, some of the longer-term projects start to build as we go into the latter parts of 2026. We've signaled that we see the margins coming to low to mid-30s, which is consistent with what we've been talking about for the last many quarters around this topic.

Got it. Thanks again for taking our questions.

Thank you.

The next question comes from Joseph Downing with Piper Sandler. Please go ahead.

Hey, everyone, and congrats on the announcement, Michael. I'm just going to attack Sterigenics from a slightly different lens here. Growth and margins in 1Q are obviously impressive, even in spite of the weather-related headwinds. But as we look at the broader inflationary backdrop, could you just help us think about the durability of Sterigenics margins through the year and whether sustained cost inflation actually creates an opportunity for the team to take incremental price throughout the year.

Yeah. Thanks, Joseph. You know, we're not seeing significant inflation in that business. We continue to manage that well. You know, our key inputs are really around labor and then gas and cobalt. We're in a good spot there. We've set pricing in such a way that we make sure our value gap is positive. You know, in the quarter, Sterigenics had about 4.5% price, which is slightly above the 4% that, you know, we've got it towards. But we continue to see that business in a good spot and be rewarded for the value it brings our customers. And we're not concerned about anything materially on the inflation side as we sit here today.

Got it. Thanks, Michael. And then you just referenced it earlier, but on that large customer onboarding that should come on later this year, Is there any more detail you can provide there about maybe sizing the customer or how to think about the ramp throughout the rest of the year, and also if that's a part of the guide?

Yeah, so that is assumed in our guide. It'll come late into the year. You know, it's a meaningful customer, but it's not, you know, crazy size. We're not building a facility or anything anywhere near that for that kind of business. But it's a significant win for us from both, you know, just morale and just helping reinforce the value prop of the company. But overall, you know, we've got that built into our outlook for the rest of this year in a guide, and you'll see it late in the year.

Great. I appreciate that.

The next question comes from Luke Sergo with Barclays. Please go ahead.

This is Salmon for Luke. Thanks for taking the question. Michael, congrats on the 10 years of the company. It's been a pleasure working with you, and best of luck as the executive chair. Sure. I wanted to talk a little bit about the Trump administration and their announcement to potentially permanently scale back some of the ethylene oxide emissions regulations. Could you talk about like the different scenarios that might come out of that and what the implications might be from like a top line perspective? I know that has been kind of talked about as a potential opportunity with like higher regulations on some of the smaller players in the industry. and, you know, to, like, how that might affect CapEx spend, both, like, in the near term and the long term.

Yeah. Thanks, Sam, for your comments and questions. So, you know, we are executing, as you know, we've spent a significant amount of CapEx and Sterigenics, approximately $200 million over the duration on what we call general facility enhancements for this ethylene oxide activity. The team is doing a very good job executing on that. We should have the vast majority of that completed here in 2026. There's a rule out there today that has got another couple of years before it's required to meet those requirements, but now there's a new proposed rule out there. Listen, we're going as if the rule that's in place is going to be the requirement, and our teams are aligned and engineering teams are executing along those plans. You know, I'm not exactly sure how the administration is going to rule on this. our job is to make sure we're operating in a safe and compliant manner, and we're taking all actions that we can to put the facility in the best place possible. So we're moving forward with those plans. We will provide comments, just like many others in the industry, on the new proposed rule. These are still going to be, based on what we saw in the proposed rule, they're going to be tough restrictions. They're a little easier than the rule that was just recently put out, but they're still tough and challenging rules. But we feel very well position to be able to to meet those requirements. As far as creating opportunities for us, depending on exactly what the final rule is and the timing, that will determine how much opportunity. I would tell you, you know, we've got a couple opportunities. One customer we just referenced that is converting over to us, and then there's some other smaller ones that we continue to have dialogue and we're seeing some opportunity with. I would say that activity slowed down a little bit over the last several quarters with this uncertainty of the timing of the new rule requirements, but again, we feel very well positioned for whatever the rule may be, and we're just going to make sure that we operate in a safe and compliant manner for all our stakeholders, employees, as well as communities.

Got it. Thank you, Michael. Maybe an unrelated follow-up on Nordian pricing. I think that came in slightly below the usual at like 2.1%. Anything significant to call out there?

I would tell you, you know, we've got a long-range guide for the company at 3% to 4%. We said Nordian would be on the low end of that, you know, around 3%. You ought to be thinking about that. It's just a matter of timing and customer mix on which customers got shipments within the quarter. We're fine on price execution in Nordian and across the business.

The next question comes from Casey Woodring with J.P. Morgan. Please go ahead.

This is Jayden on for Casey. I just had a quick one on pricing as well. but could you just share or walk us through your pricing assumption for 2026 and highlight if there's anything that's changed by segment? I know you just mentioned Nordean, but anything else would be helpful.

Yeah, no, nothing has changed from what we've communicated previously. Price would be the 3% to 4% range. As I mentioned, just Minsko and Nordean would be on the low end of that range. Nelson would be on the low end of that range, and Sarah Jenks would be on the high end of that range. We don't see anything changing as far as our...

All right. Thank you.

The next question comes from Ryan Halston with RBC Capital Markets. Please go ahead.

Hey, team. This is Kevin on for Ryan. Just two quick ones for us. Was there any extra selling day benefit in 1Q26? And if so, how much did that impact your guys' growth rates?

Not that I – no, very minimally.

Okay. Awesome. And then kind of unrelated here, but in 25, you guys talked about your XBU customers kind of growing ahead of total company growth. Can you guys just comment on how XBU is performing through the first half of 26 at this point and any opportunities you guys have to further accelerate that XBU penetration?

Yep, thanks for the question. We had a good first quarter in that area. We had growth again. And as I mentioned earlier, our customer satisfaction scores were very positive with significant growth on that front as well. So overall, the work is going very well in the XBU. And remember, you know, a lot of strength around the embedded labs within the Nelson, within Sterigenics, the Nelson labs that coexist or, you know, we continue to execute in that area as well. So, XPU is pretty well situated.

Gotcha. Thank you.

Again, if you have a question, please press star then 1. The next question comes from Michael Polark with Wolf Research. Please go ahead.

Good morning. Hey, Michael. Congrats. I would have thought if you were making a transition, you would have shed the investor relations hat so you didn't have to deal with folks like me and my clients. But I was only surprised to see that's still part of your ongoing commitment.

Trust me, I was trying to shed the litigation, but the board wouldn't let me. Trust me on that.

My other joke that I was noodling on was I'm sure you can imagine more fun things than defending multi-state toxic tort cases. So anyways, but yes, congrats. All right. Two for me. In the quarter, appreciate the weather call out for Sterigenics. If I recall, part of the 1Q guidance also considered kind of excess EO maintenance downtime. I didn't hear that spiked out. Would you flag that as a significant item in the quarter on Sterigenics volumes? And then, John, maybe for the rest of the year, what's kind of the maintenance schedule across the network? Anything unusual you would have us think about 2Q, 3Q, 4Q?

Yeah, I'll turn to John the answer. Just one point, Michael, on that. It's one thing, as I mentioned, about the customer coming on board, also the emphasis we're getting from our customers on some of the outlook, as well as the Hall River coming on. The thing I failed to mention was also the number of days out in the second half will be lower. John, go ahead, John.

I wouldn't add anything other than to reiterate that point. The downtime days are a head win year over year in the first half and turns to a tail win in the second half.

Helpful. And then the second one, total squint, but Nelson for the second quarter, slight return or return to slight growth is slight. Is that 1% or is that something better? Thank you.

I would think in the range you're talking or below.

Okay. Thank you.

This concludes our question and answer session. I would like to turn the conference over to Michael Petras for any closing remarks.

Great. Thank you. You know, as we move through 2026, we're encouraged by momentum and a strengthening financial position remain confident in our ability to drive long-term growth, strong cash flow, and shareholder value. Our leadership in a large and growing market, global scale, the regulatory expertise, accelerating free cash flows, and disciplined capital allocation positions really well for sustainable growth. So we look forward to seeing many at the conferences coming up here this spring and early summer, but thank you for your continued support and have a good day. Thank you.

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.